Search

Dupilumab, a drug approved by the US Food and Drug Administration, has shown safety and efficacy in treating eosinophilic esophagitis (EoE), a specific immune disorder. The drug inhibits interleukin 4 and IL-13 signaling and has been found to improve symptoms and achieve histologic remission in patients with EoE. However, it is not suitable for every patient, and a tempered approach is recommended. Challenges to widespread use include cost and insurance coverage, as well as the need for long-term data. Further research is needed to explore the drug's effectiveness in diverse populations and its use in different patient groups. [Extracted from the article]

Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the esophagus that affects both children and adults. The global incidence of EoE has been increasing, particularly in the United States, Western Europe, and Australia. Environmental and food exposures, as well as genetics, may play a role in triggering EoE. Diagnosis requires knowing the symptoms, excluding other disorders, and performing a biopsy. Treatment approaches for EoE include diet, drugs, and dilation. Reducing diagnosis delays is crucial for limiting EoE-associated morbidity. [Extracted from the article]

They were developed jointly by the European Society for Paediatric Gastroenterology, Hepatology and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Awareness of non-EoE EGIDs has been higher among pediatric gastroenterologists than among those treating adult disease because pediatric gastroenterologists have always obtained biopsies of the intestinal tract, Dr. Furuta noted. Guideline development was funded by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. [Extracted from the article]

The US Food and Drug Administration (FDA) has approved budesonide oral suspension (Eohilia, Takeda) as the first oral treatment for eosinophilic esophagitis (EoE). Budesonide oral suspension is a corticosteroid that can be used for 12 weeks to treat EoE in adults and children as young as 11 years old. The medication will be available in single-dose stick packs by the end of February. The approval was based on two studies that showed the effectiveness of budesonide in achieving histologic remission and improving dysphagia symptoms. The most common side effects include respiratory tract infection, gastrointestinal mucosal candidiasis, and headache. [Extracted from the article]

Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the esophagus that affects both children and adults. The global incidence of EoE has been increasing, particularly in the United States, Western Europe, and Australia. Environmental and food exposures, as well as genetics, may play a role in triggering EoE. Diagnosis requires knowing the symptoms, excluding other disorders, and performing a biopsy. Treatment approaches for EoE include diet, drugs, and dilation. Reducing diagnosis delays is crucial for limiting EoE-associated morbidity. [Extracted from the article]

The article discussed a study which reported the effectiveness of the ulcerative colitis drug etrasimod in eosinophilic esophagitis (EoE), with notable reductions seen in eosinophils. Topics include a statistically significant decrease in only one segment of the trial participants, treatment-emergent adverse events, and a limitation of the study.

A recent analysis of published trials of the drug dupilumab for atopic dermatitis (AD) suggests that the prevalence of clinically meaningful conjunctivitis in patients taking dupilumab is around 2%. This conjunctivitis most commonly occurs within the first 16 weeks of therapy. The analysis also found that adults with AD have an increased risk of developing ocular surface diseases, including conjunctivitis, compared to the general population. The study raises questions about how frequently dupilumab-induced conjunctivitis occurs and how it can be differentiated from conjunctivitis that is part of the underlying AD process. [Extracted from the article]

A study presented at the annual meeting of the American College of Gastroenterology found that the use of fluticasone and budesonide, inhaled steroids, for eosinophilic esophagitis (EoE) during pregnancy did not have any significant adverse effects on maternal or fetal outcomes. The study included 1,263 pregnant patients with EoE and compared the rates of various complications between those who used steroids during pregnancy and those who did not. The results showed that there were no significant differences in the rates of spontaneous abortion, placenta previa, preeclampsia, premature delivery, HELLP syndrome, hyperemesis gravidarum, or major congenital abnormalities between the two groups. The findings provide reassurance that the use of steroids in pregnant patients with EoE is not associated with an increased risk of worse outcomes. [Extracted from the article]